EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers

Lu Liu, Dandan Liang, Cui Wang, Jian Li, Jie Tang, Weimin Li, Xijie Yu

International Journal of Biological Sciences · 22.07.2026 · 22 (13) · 6985-7002

DOI: 10.7150/ijbs.131261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Biological Sciences, erschienen am 22.07.2026. Verfasst von Lu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Endocrinology and Metabolism, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Lung Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in hematological malignancies. However, its efficacy in solid tumors such as lung cancer remains constrained by the immunosuppressive tumor microenvironment (TME). Aberrant vascular architecture and dense stroma constitute major physical barriers that hinder CAR T cell infiltration. Additionally, an immunosuppressive cellular network, dominated by myeloid-derived suppressor cells and tumor-associated macrophages, further restricts CAR T cell expansion and function. Moreover, immune checkpoint signaling, inhibitory cytokines, dysregulated chemokine gradients, and metabolic reprogramming under hypoxia collectively create a hostile biochemical and metabolic milieu that drives CAR T cell dysfunction and exhaustion. This review systematically outlines these multifactorial barriers within the lung cancer TME and discusses emerging strategies, including combinatorial approaches, engineered CAR T designs, and microenvironment-modulating platforms, that aim to improve the therapeutic efficacy of CAR T cell therapy in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentLung NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsT-LymphocytesT-Cell Exhaustion

Stichwörter der Autor:innen

CAR T cell therapyimmunotherapylung cancersolid tumorstumor microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Laboratory of Endocrinology and Metabolism, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
  • Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Chengdu, China.
  • Department of Endocrinology and Metabolism, Shandong Second Provincial General Hospital, No. 4, Duanxing West Road, Jinan, Shandong Province, China.

Zitieren

APA

Liu, L., Liang, D., Wang, C., Li, J., Tang, J., Li, W., & Yu, X. (2026). CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers. International Journal of Biological Sciences, 22(13), 6985-7002. https://doi.org/10.7150/ijbs.131261

Vancouver

Liu L, Liang D, Wang C, Li J, Tang J, Li W, et al. CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers. International Journal of Biological Sciences. 2026;22(13):6985-7002. doi:10.7150/ijbs.131261

BibTeX
@article{Liu2026,
  author = {Liu, Lu and Liang, Dandan and Wang, Cui and Li, Jian and Tang, Jie and Li, Weimin and Yu, Xijie},
  title = {CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  volume = {22},
  number = {13},
  pages = {6985--7002},
  doi = {10.7150/ijbs.131261}
}
Kostenlos starten →